Loading…
Employees: 186
Size Sight Sciences (SGHT) is a United States Health Care company (Medical Specialties) with a market value of $555M, the 2622nd largest of 3,117 United States companies the cockpit tracks. Shares closed at $5.55 on 6 Nov 2026.
Performance Over six months the shares fell 14.2%, against -13.2% for the median peer and -1.1% for the United States market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue grew 9.3% over the last twelve months (peer median +4.2%); the operating margin is -33.4% (peer median 2.7%).
Valuation It trades at 6.2× enterprise value to sales against a peer median of 3.4× (5th most expensive of 18).
Capital Return on invested capital runs 161.9 points below its cost of capital (16.2% WACC).
Short interest Short interest is 2.2% of the free float (15 Oct 2026).
Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $83.4M | $77.4M | $79.9M | $81.1M | $71.3M |
| Revenue growth | — | -3% | -1% | +14% | — |
| Gross profit | $73.3M | $66.7M | $68.3M | $69.2M | $59.0M |
| EBITDA | -$27.5M | -$36.6M | -$49.8M | -$56.7M | -$82.7M |
| Net income | -$29.8M | -$38.4M | -$51.5M | -$55.5M | -$86.2M |
| Free cash flow | -$23.3M | -$29.9M | -$22.7M | -$48.0M | -$76.9M |
| Capital expenditure | $93,000 | $224,000 | $385,000 | $791,000 | $970,000 |
| Total debt | $42.0M | $40.8M | $40.4M | $35.4M | $35.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SGHT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.7% | -4.3% | 5th highest of 20 |
| 6-month return | -14.2% | -13.2% | 9th lowest of 20 |
| Distance from 52-week high | -39.9% | -37.3% | 10th lowest of 20 |
| Revenue growth (TTM) | +9.3% | +4.2% | 8th highest of 20 |
| Operating margin | -33.4% | 2.7% | 3rd lowest of 20 |
| EV / Sales | 6.2× | 3.4× | 5th most expensive of 18 |
| ROIC minus cost of capital | -161.9 pp | -1.6 pp | lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sight Sciences SGHT | United States | $555M | -14% | +9% | -33% | 6.2× | n/a | n/a |
| MedicalSystem Biotechnology 300439.SZ | China | $556M | -4% | +14% | 2% | 1.7× | 7.4% | -7.8% |
| Anteris Technologies Global AVR | United States | $555M | -14% | -10% | -4,738% | 134.2× | n/a | n/a |
| Zhejiang Orient Gene Biotech 688298.SS | China | $559M | -17% | +18% | -60% | 2.0× | n/a | n/a |
| Anbio Biotechnology NNNN | United States | $560M | -85% | +10% | 67% | n/a | n/a | n/a |
| Nanjing Vishee Medical Technology 688580.SS | China | $550M | -40% | +7% | 24% | 6.0× | 22.3% | +4.2% |
| Sahajanand Medical Technologies SMT.NS | India | $566M | n/a | n/a | n/a | n/a | n/a | n/a |
| Myriad Genetics MYGN | United States | $566M | +38% | -3% | -11% | 0.8× | n/a | n/a |
| Guangdong Hybribio Biotech 300639.SZ | China | $568M | -5% | -7% | 4% | 4.5× | 2.7% | -13.2% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $542M | -3% | +23% | 31% | 8.0× | 6.3% | +24.4% |
| Assure Tech (Hangzhou) 688075.SS | China | $538M | -25% | -21% | -7% | n/a | n/a | n/a |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $537M | -32% | +9% | 3% | 2.3× | n/a | n/a |
| medmix MEDX.SW | Switzerland | $537M | +24% | -7% | 6% | 1.5× | 5.0% | +5.0% |
| Jin Medical International ZJYL | United States | $532M | +53% | -14% | 2% | 26.5× | n/a | n/a |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $581M | -10% | +6% | 9% | 2.8× | 11.6% | +6.5% |
| Tactile Systems Technology TCMD | United States | $583M | +1% | +14% | 9% | 1.5× | 7.8% | +12.0% |
| Hangzhou Alltest Biotech 688606.SS | China | $521M | -15% | 0% | 13% | 1.6× | -3.9% | -4.3% |
| Guangdong Biolight Meditech 300246.SZ | China | $519M | -23% | +4% | -9% | 3.4× | 14.8% | -4.7% |
| Delcath Systems DCTH | United States | $518M | +30% | +36% | -2% | 4.5× | 10.1% | +120.2% |
| Nanosonics NAN.AX | Australia | $599M | -13% | +3% | 7% | 3.6× | 34.4% | +6.7% |
| Contec Medical Systems 300869.SZ | China | $600M | -23% | -2% | -16% | 6.3× | 17.3% | -19.8% |